Work

Supplementary Methods, Figures 1 - 7 from Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 422KB, S1. Cell survival as measured by a clonogenic assay. S2. BRCT I domain of XRCC1. S3. Characterization of cell lines by western blotting. S4. Characterization of full-length wild-type XRCC1 and L360R mutant XRCC1 mouse proteins. S5. Inhibitory effect of olaparib (O) or veliparib (V) (10 mM) on PAR accumulation in MMS-treated (10 mM for 20 min at 4 degrees C) wild-type (red) and pol beta null cells (gray). S6. Effect of PARPi on sensitivity of wild-type (16.3, closed red symbols) and pol beta null (19.4, open black symbols) cells to MMS. S7. Sensitivity of pol beta- and XRCC1-deficient cell lines to olaparib and veliparib.

DOI: 10.1158/1541-7786.22513761.v1

Authors: Julie K. Horton, Donna F. Stefanick, Rajendra Prasad, Natalie R. Gassman, Padmini S. Kedar, Samuel H. Wilson

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362537277

Cites: 6

Cited by:

Related to: 10